Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma

Dirk Rades, Stefan Huttenlocher, Niklas Gebauer, Dagmar Hornung, Ngo Thuy Trang, Mai Trong Khoa, Steven E. Schild

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

Original languageEnglish (US)
Pages (from-to)3571-3574
Number of pages4
JournalAnticancer Research
Volume35
Issue number6
StatePublished - Jun 1 2015

Fingerprint

Radiosurgery
Renal Cell Carcinoma
Neoplasm Metastasis
Multivariate Analysis
Survival
Neoplasms
Odds Ratio
Radiation

Keywords

  • Cerebral metastases
  • Freedom from new cerebral metastases
  • Local control
  • Renal cell carcinoma
  • Stereotactic radiosurgery
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rades, D., Huttenlocher, S., Gebauer, N., Hornung, D., Trang, N. T., Khoa, M. T., & Schild, S. E. (2015). Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Research, 35(6), 3571-3574.

Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. / Rades, Dirk; Huttenlocher, Stefan; Gebauer, Niklas; Hornung, Dagmar; Trang, Ngo Thuy; Khoa, Mai Trong; Schild, Steven E.

In: Anticancer Research, Vol. 35, No. 6, 01.06.2015, p. 3571-3574.

Research output: Contribution to journalArticle

Rades, D, Huttenlocher, S, Gebauer, N, Hornung, D, Trang, NT, Khoa, MT & Schild, SE 2015, 'Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma', Anticancer Research, vol. 35, no. 6, pp. 3571-3574.
Rades D, Huttenlocher S, Gebauer N, Hornung D, Trang NT, Khoa MT et al. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Research. 2015 Jun 1;35(6):3571-3574.
Rades, Dirk ; Huttenlocher, Stefan ; Gebauer, Niklas ; Hornung, Dagmar ; Trang, Ngo Thuy ; Khoa, Mai Trong ; Schild, Steven E. / Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. In: Anticancer Research. 2015 ; Vol. 35, No. 6. pp. 3571-3574.
@article{39f81ea0ee8d4290806569621a168a8f,
title = "Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma",
abstract = "Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81{\%} vs. 50{\%} at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75{\%} vs. 62{\%} at 12 months; p=0.42) or survival (16{\%} vs. 56{\%} at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.",
keywords = "Cerebral metastases, Freedom from new cerebral metastases, Local control, Renal cell carcinoma, Stereotactic radiosurgery, Survival",
author = "Dirk Rades and Stefan Huttenlocher and Niklas Gebauer and Dagmar Hornung and Trang, {Ngo Thuy} and Khoa, {Mai Trong} and Schild, {Steven E.}",
year = "2015",
month = "6",
day = "1",
language = "English (US)",
volume = "35",
pages = "3571--3574",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma

AU - Rades, Dirk

AU - Huttenlocher, Stefan

AU - Gebauer, Niklas

AU - Hornung, Dagmar

AU - Trang, Ngo Thuy

AU - Khoa, Mai Trong

AU - Schild, Steven E.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

AB - Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

KW - Cerebral metastases

KW - Freedom from new cerebral metastases

KW - Local control

KW - Renal cell carcinoma

KW - Stereotactic radiosurgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84931418205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931418205&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 3571

EP - 3574

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -